Invesco Ltd. Verastem, Inc. Transaction History

Invesco Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $66,078 - $118,552	-64,783 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.06 - $2.1 $2,383 - $4,722	2,249 Added 3.6%	64,783 $91,000
Q4 2021 Feb 14, 2022	SELL	$2.05 - $3.2 $11,658 - $18,198	-5,687 Reduced 8.34%	62,534 $128,000
Q3 2021 Nov 15, 2021	SELL	$2.54 - $4.07 $2.13 Million - $3.41 Million	-837,848 Reduced 92.47%	68,221 $210,000
Q2 2021 Aug 17, 2021	BUY	$2.57 - $4.85 $2.21 Million - $4.16 Million	858,150 Added 1790.83%	906,069 $3.69 Million
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $15,608 - $23,166	8,215 Added 20.69%	47,919 $118,000
Q4 2020 Feb 16, 2021	BUY	$1.15 - $2.4 $31,107 - $64,920	27,050 Added 213.77%	39,704 $85,000
Q3 2020 Nov 16, 2020	BUY	$1.11 - $1.68 $507 - $767	457 Added 3.75%	12,654 $15,000
Q2 2020 Aug 14, 2020	BUY	$1.69 - $4.2 $20,612 - $51,227	12,197 New	12,197 $21,000
Q1 2019 May 15, 2019	SELL	$2.79 - $4.09 $81,024 - $118,777	-29,041 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.23 - $7.01 $93,802 - $203,577	29,041 New	29,041 $98,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.25B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.